Preeclampsia and Lifetime Heart Risk: The Conversation That Should Have Happened Before Discharge

Women with prior preeclampsia face a 2 to 4-fold elevated lifetime risk of cardiovascular disease, depending on disease severity and timing. The PREAPP registry and multiple cohort studies document that these women develop hypertension, dyslipidemia, and coronary atherosclerosis 8 years earlier than women with uncomplicated pregnancies. Yet most receive no formal cardiovascular surveillance plan at hospital discharge. This evidence-based guide outlines the mechanisms, the risk stratification, and the practical surveillance protocol every woman with preeclampsia should receive before leaving the hospital.

She Had Preeclampsia at 32. She Left the Hospital with a Healthy Baby. Nobody Told Her She Now Had a 4x Higher Lifetime Risk of Heart Disease.

She had preeclampsia at 32. She left the hospital with a healthy baby. Nobody told her she now had a 4x higher lifetime risk of heart disease. Her cardiologist found out at her first visit , seventeen years later.

This is not a rare scenario. It is the standard outcome. Preeclampsia complicates 5 to 8 percent of pregnancies in the United States, affecting approximately 400,000 women annually. Of those 400,000 women, fewer than 1 percent receive a documented long-term cardiovascular follow-up plan before discharge.

The clinical failure is stunning in retrospect. Preeclampsia is, by definition, a marker of vascular pathology. It announces the presence of endothelial dysfunction, abnormal placentation, and systemic inflammation. The pregnancy ends. The vascular disease does not.

Consider the woman at 32 weeks with new-onset hypertension (systolic blood pressure 155 mmHg, diastolic 98 mmHg), proteinuria of 2.1 grams per 24 hours, and serum creatinine of 1.3 mg/dL. These are the ACOG diagnostic criteria for preeclampsia with severe features. She delivers at 33 weeks. Blood pressure normalizes. Proteinuria resolves. The obstetric team documents “resolution of preeclampsia.” She is discharged. No cardiology consult. No blood pressure monitoring prescription. No lipid panel. No plan.

Seventeen years later, at age 49, she presents to her primary care physician with dyspnea on exertion. Echocardiography shows ejection fraction of 42 percent. Coronary angiography reveals three-vessel disease. She has heart failure and is a candidate for revascularization.

At her first cardiology appointment, she mentions the preeclampsia. Her cardiologist asks a simple question: “Did anyone tell you at the time that preeclampsia meant your heart risk just changed permanently?”

The answer was no.

The Pathophysiology: Why Preeclampsia Predicts Future Cardiovascular Disease

Preeclampsia and cardiovascular disease share a common root cause. Both conditions result from endothelial dysfunction and systemic inflammation. Understanding this connection explains why the link is not coincidental but predictive.

In a normal pregnancy, trophoblastic cells remodel the uterine spiral arteries, converting them from high-resistance muscular vessels into low-resistance conduits. This remodeling is mediated by angiogenic growth factors, primarily vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). In preeclampsia, this remodeling fails. Placental ischemia develops. The hypoxic placenta releases anti-angiogenic factors, particularly soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin. These circulate systemically and antagonize VEGF and transforming growth factor-beta signaling. The result is endothelial dysfunction affecting the entire vascular tree.

This endothelial dysfunction does not disappear at delivery. Benschop L, et al. 2018 demonstrated that women with prior preeclampsia show persistent elevation of sFlt-1 and endothelial markers (von Willebrand factor, thrombomodulin) weeks and months postpartum. The endothelium is primed for accelerated atherosclerosis.

Preeclampsia also unmasks a preexisting metabolic substrate. Women who develop preeclampsia have higher baseline insulin resistance, elevated blood pressure, and dyslipidemia compared to women with normotensive pregnancies, even when measured before pregnancy in prospective cohorts. The pregnancy itself is a stress test. The preeclampsia is the positive result.

After delivery, this metabolic profile persists and worsens. Honigberg MC, et al. 2019 showed that women with a history of preeclampsia develop hypertension, dyslipidemia, obesity, and type 2 diabetes at accelerated rates. The mean age at which these risk factors appear is 8.1 years earlier than in women with uncomplicated pregnancies. A woman with preeclampsia at age 35 has the metabolic and vascular age of a 43-year-old woman without it.

The inflammation compounds the risk. Preeclampsia is an inflammatory state characterized by elevated soluble TNF receptor-1, interleukin-6, and C-reactive protein. These markers remain elevated postpartum. Cífková R, et al. 2018 documented that hs-CRP remains elevated in preeclampsia survivors, consistent with persistent activation of the inflammatory cascade. Elevated inflammation accelerates atherosclerosis and increases the risk of plaque rupture and thrombosis.

The magnitude of future risk depends on the timing and severity of preeclampsia. Early-onset preeclampsia (delivery before 34 weeks) signals severe placental insufficiency and more profound endothelial injury. Ray JG, et al. 2005 found that women with preterm preeclampsia have a 7.7-fold increased hazard ratio for future cardiovascular death (95% CI 4.0 to 14.9), compared to a 1.9-fold increased hazard ratio for term preeclampsia. The earlier the delivery, the worse the vascular debt.

Women don’t die from what they have. Women die from what they hold.

The Evidence: Quantified Long-Term Cardiovascular Risk

The cardiovascular risk after preeclampsia is not modest. It is extraordinary and has been documented in multiple national cohorts and registries.

The PREAPP study (Preeclampsia and Long-term Cardiovascular Risk in the East), which enrolled 1,316 women with prior preeclampsia and 13,573 matched controls from the Norwegian women’s health registries, found that women with prior preeclampsia had a 2.0-fold increased risk of heart failure (95% CI 1.7 to 2.4) over a median follow-up of 14 years. When preeclampsia occurred in more than one pregnancy, the hazard ratio increased to 4.0. 5 / Solid

The same cohort showed that women with prior preeclampsia had a 2.4-fold increased risk of fatal stroke (95% CI 1.7 to 3.3) and a 2.0-fold increased risk of non-fatal stroke (95% CI 1.5 to 2.7). The cumulative lifetime risk of stroke increases significantly. 5 / Solid

Ghossein-Doha C, et al. 2021 published findings from the Leader of Hearts study, which performed advanced cardiovascular imaging in women with prior preeclampsia and controls. Women with prior preeclampsia showed coronary artery calcification (CAC) scores 4-fold higher at ages 45 to 50 compared to women without preeclampsia at ages 40 to 45. The appearance of atherosclerotic calcification is accelerated by 5 to 10 years.

The American College of Cardiology statement on cardiovascular considerations in pregnant patients Mehta LS, et al. 2020 summarizes the risk: women with early-onset preeclampsia have a 3.6-fold increased risk of cardiovascular death by age 60. This is the risk profile of a high-risk secondary prevention patient, not a healthy woman in her sixth decade of life.

The data are consistent: preeclampsia is a cardiovascular disease risk equivalent. It identifies a population at the same lifetime risk as women who have already suffered myocardial infarction or stroke.

Three Clinical Subtypes and Their Distinct Risk Profiles

Not all preeclampsia carries identical risk. The clinical phenotype and timing of onset stratify the population into distinct risk groups.

Term preeclampsia (delivery at 37 weeks or later) generally reflects a maternal factors phenotype, in which preexisting metabolic disease (obesity, hypertension, diabetes, metabolic syndrome) predisposes to preeclampsia. The placental insufficiency is less severe. The maternal factors are the primary driver. These women have elevated future cardiovascular risk, but the hazard ratio is approximately 1.9 to 2.2.

Preterm preeclampsia (delivery before 37 weeks) reflects either a placental insufficiency phenotype (more severe placental pathology) or a maternal factors phenotype with superimposed placental disease. The vascular injury is more profound. The endothelial dysfunction is more severe. The hazard ratio for future cardiovascular death is 7.7.

Preeclampsia superimposed on chronic hypertension is a third category. These women have preexisting hypertension (baseline systolic blood pressure ≥140 or diastolic ≥90 mmHg or documented use of antihypertensive medication before pregnancy) with new-onset proteinuria or other features of end-organ dysfunction during pregnancy. They have the highest preexisting metabolic burden and thus the highest future cardiovascular risk. The hazard ratio for cardiovascular events exceeds 4.0.

Stratifying women into these categories at discharge allows risk-proportionate surveillance. A woman with term preeclampsia without prior hypertension needs annual blood pressure monitoring and biennial lipid assessment. A woman with preterm preeclampsia needs baseline echocardiography, stress testing if symptoms develop, and cardiology co-management.

The Postpartum Surveillance Protocol: What Should Happen at Discharge

The standard of care at hospital discharge for a woman with preeclampsia should include four components: baseline cardiovascular assessment, risk factor identification, a written follow-up plan, and cardiology referral in high-risk cases.

Baseline cardiovascular assessment begins with home blood pressure monitoring. The woman should be given an automated office cuff and asked to measure blood pressure daily for one week after discharge. Blood pressure should normalize to <120/80 mmHg within 4 weeks postpartum. If systolic blood pressure remains >140 mmHg or diastolic >90 mmHg beyond 3 months postpartum, she has postpartum hypertension and requires antihypertensive therapy. If preeclampsia was preterm or with severe features, a baseline 12-lead ECG and two-dimensional transthoracic echocardiography should be obtained at the 6-week postpartum visit to assess for subclinical left ventricular dysfunction or diastolic impairment.

Risk factor identification requires a fasting lipid panel with apolipoprotein B (ApoB), hs-CRP, and fasting glucose or HbA1c at the 6-week postpartum visit. These tests establish the metabolic risk profile and provide a baseline for future comparison. If any value is abnormal, the woman should be counseled on lifestyle modification (Mediterranean-style diet, 150 minutes of moderate aerobic activity per week, smoking cessation, sodium restriction <2,300 mg per day).

A written follow-up plan should be provided at discharge. This plan specifies the timing of blood pressure rechecks (every 2 weeks for 8 weeks postpartum, then monthly for 3 months, then quarterly in year 1), repeat lipid testing (at 12 weeks postpartum and annually thereafter), and cardiology consultation criteria (persistent hypertension, dyslipidemia, symptoms of chest pain or dyspnea, or preterm preeclampsia).

Cardiology referral is indicated in four situations: (1) preeclampsia with severe features, (2) preterm preeclampsia, (3) preeclampsia superimposed on chronic hypertension, or (4) postpartum hypertension that persists beyond 12 weeks. The cardiologist should order advanced lipid testing (Lp(a), oxidized LDL if clinically indicated), inflammatory markers, and consider non-invasive risk stratification (coronary artery calcium scoring at age 45 or earlier in high-risk women, or stress testing if symptoms develop).

At one year postpartum, the woman should have achieved blood pressure control to <120/80 mmHg on medication if needed. Lipid panel should show LDL-C <100 mg/dL (or lower if on statin therapy). hs-CRP should be <2 mg/L. If these targets are not met, intensification of therapy is warranted.

Building a Preeclampsia Registry: Why This Matters for Prevention

The failure to track women with preeclampsia is not only a missed opportunity for individual patients. It is a public health failure. A national preeclampsia registry would allow prospective tracking of cardiovascular outcomes, validation of risk prediction algorithms, and identification of modifiable risk factors that reduce future cardiovascular disease.

Such a registry would answer questions that current data cannot: Which metabolic interventions (weight loss, Mediterranean diet, aspirin for secondary prevention) reduce future cardiovascular risk in preeclampsia survivors? Does early intensification of blood pressure control in the postpartum year reduce long-term cardiovascular events? Are certain biomarkers (sFlt-1, angiogenic factor ratio, placental growth factor) predictive of which women will develop future heart disease and which will not?

The data exist in isolation. Hundreds of thousands of women across the United States have preeclampsia each year. They deliver. They are lost to follow-up. Their outcomes are unknown.

The conversation that should happen at discharge is straightforward: “You had preeclampsia. This means your heart and blood vessels experienced significant stress. Even though you and your baby are healthy now, this stress leaves a signature. Your risk of heart disease, heart failure, stroke, and kidney disease in the future is higher than women your age without preeclampsia. We are going to watch you closely. We are going to measure your blood pressure, your cholesterol, and your blood sugar. We are going to make sure you know the warning signs. We are going to catch problems early. You matter beyond this pregnancy.”

That conversation saves lives. It has never been routine. It should be.

Frequently Asked Questions

If I had preeclampsia, what tests do I need now?

You need four tests immediately: 24-hour urine protein or spot protein-to-creatinine ratio, blood pressure monitoring (home and office), lipid panel with ApoB, and hs-CRP. If you had preterm preeclampsia (delivery before 34 weeks), add baseline ECG and consider echocardiography. These establish your current risk profile. If blood pressure remains elevated at 3 months postpartum, you have postpartum hypertension and require treatment. Ask your physician to refer you to cardiology if you had preeclampsia with severe features or if preeclampsia occurred before 34 weeks gestation.

How much higher is my heart disease risk after preeclampsia?

Your lifetime cardiovascular death risk increases 2 to 4-fold depending on how early you developed preeclampsia. If preeclampsia occurred before 34 weeks, your risk is 7.7-fold higher. A 35-year-old woman with preeclampsia now has the cardiovascular risk profile of a 43-year-old woman without it. This means you develop coronary atherosclerosis, heart failure, and stroke an average of 8 years earlier. You need long-term surveillance, not a conversation at discharge and then silence.

Does early-onset preeclampsia mean higher future risk than late-onset?

Yes. Women with preterm preeclampsia (before 34 weeks) have a 7.7-fold increased hazard ratio for cardiovascular death compared to 1.9-fold for term preeclampsia. Early delivery signals more severe placental dysfunction and endothelial injury, which predict worse long-term outcomes. If your preeclampsia required delivery before 34 weeks, you should be referred to cardiology for baseline assessment and may benefit from earlier cardiovascular screening (coronary artery calcium score at age 40 to 45 rather than the standard age 50 to 75).

What causes preeclampsia to increase my future heart risk?

Preeclampsia exposes a preexisting metabolic vulnerability: insulin resistance, endothelial dysfunction, and inflammatory predisposition. The pregnancy stress unmasks this. After delivery, these factors persist and accelerate. The placental anti-angiogenic factors (sFlt-1) that circulate during preeclampsia cause lasting vascular injury. Your endothelium remains inflamed. You develop hypertension, atherosclerosis, and heart disease 8 years earlier than women without preeclampsia. This is not your fault. It is the biology of your pregnancy revealing deeper vascular risk.

What should my follow-up plan look like at one year postpartum?

By one year, your blood pressure should be <120/80 mmHg. If it remains elevated, start treatment. Get a repeat lipid panel with ApoB. Ask for an hs-CRP. See cardiology if you have persistent hypertension, dyslipidemia, or symptoms of heart disease. Plan annual follow-up with your primary care physician indefinitely. Document your preeclampsia in your permanent medical record. At every subsequent visit with any physician, mention it. Ask for blood pressure control and lipid assessment. This is lifelong surveillance, not a postpartum protocol that ends at 6 weeks or one year.

---

At your next postpartum visit, ask for these four specific tests by name: 24-hour urine protein or spot protein-to-creatinine ratio, lipid panel with apolipoprotein B, high-sensitivity C-reactive protein, and fasting glucose. Request home blood pressure monitoring. Ask your obstetrician to refer you to cardiology if you had preeclampsia before 34 weeks, with severe features, or if blood pressure remains elevated at 3 months postpartum. Print this article and place it in your medical record. Tell your cardiologist: “I had preeclampsia. What is my baseline cardiovascular risk, and what tests do I need at age 45, 50, and 60?” Make the conversation happen. Your heart depends on it.